On March 24, 2026 Peptomyc reported the closing of a €5 million equity financing to advance the next stage of development of OMO-103, the first direct MYC inhibitor with clinical validation. The financing was led by Alta Life Sciences and Aurora Science, with participation from new investors, the EIC Fund, part of the European Innovation Council, and Laudecum, as well as follow-on participation from existing investor, CDTI Innovación, through its SICC Innvierte.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The proceeds from the financing will be used to advance OMO-103 toward its next development milestones, including the completion of ongoing clinical studies, continued progress on manufacturing readiness for later-stage development, and ongoing strategic partnering activities. The financing reflects continued support for Peptomyc’s progress.
"We are grateful for the support of our investors and for the confidence they have placed in Peptomyc as we advance OMO-103 into later-stage clinical development," said Jesús Martin Garcia, CEO of Peptomyc. "This financing provides us with the resources to execute on our ongoing studies, strengthen our development capabilities, and support ongoing discussions with potential pharmaceutical partners."
Montserrat Vendrell, Partner at Asabys Partners and Board Member at Peptomyc, commented: "Peptomyc represents an important opportunity in oncology. OMO-103 is the first and only direct MYC inhibitor that has demonstrated a favorable safety profile in clinical trials, with promising signs of biological and clinical activity. MYC is a key oncogene in approximately 70% of cancers, and Peptomyc’s ability to target this previously perceived ‘undruggable’ target opens new therapeutic possibilities. We are excited to continue supporting the team at this important stage of development."
OMO-103 is the first direct MYC inhibitor with clinical validation, having demonstrated a favorable safety profile, target engagement, and early signs of clinical activity. Peptomyc is currently advancing OMO-103 across three ongoing clinical studies, including a Phase 1b trial in metastatic pancreatic cancer, a Phase 2 trial in osteosarcoma, and a Window-of-Opportunity study in pancreatic cancer.
In parallel, Peptomyc is continuing discussions with potential pharmaceutical partners to explore collaborations aimed at accelerating the development of OMO-103. Together with ongoing clinical execution and manufacturing readiness activities, these discussions are intended to support the company’s progress toward the next stage of development for OMO-103.
(Press release, Peptomyc, MAR 24, 2026, View Source [SID1234663865])